// App-Quantinova.ai

: CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension

Researchers

Presenter

  • Luke Howard

Principal Investigators

  • Kelly Chin

  • Yiu-Lian Fong

  • Cynthia Gargano

  • Dimitri Stamatiadis

  • Bradley Maron

  • Ioana Preston

  • Deborah Quinn

  • Stephan Rosenkranz

  • Mark Toshner

  • Martin Wilkins

  • David Kiely

Medical Centers

  • National Pulmonary Hypertension Service, Hammersmith Hospital, London, United Kingdom,

  • UT Southwestern Medical Centre - Dallas - United States of America

  • Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Tufts Medical Center, Boston, United States

  • University of Cologne, Cologne, DE, Germany

  • University of Cambridge, Cambridge, United Kingdom

  • Imperial College, London, United Kingdom

  • Royal Hallamshire Hospital, Sheffield, United Kingdom

Locations

  • United Kingdom

  • United States

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Chronic thromboembolic pulmonary hypertension

  • Pulmonary arterial hypertension

Biomarkers

  • Volatile organic compounds

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT04193046

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved